Ohio State

Patients whose tumors had methylated MGMT promoters were more likely to survive than those that did not after combination treatment with radiotherapy and temozolomide.

Science reports that Ohio State University cancer researcher Ching-Shih Chen resigned due to misconduct findings.

Prospective panel sequencing on colorectal cancer patients picked up Lynch syndrome with sensitivity and specificity that met or exceeded gene-by-gene tests.

The researchers plan to add the MSI detection capabilities to an NGS panel and will use the information to guide cancer patients to precision medicine trials.

Croce's Suit

Ohio State's Carlo Croce sues the New York Times over its article on research misconduct allegations, Retraction Watch reports.

This Week in Science

In Science this week: genomic investigation of maize's adaption to temperate climates, and more.

Concerns Issued

Retraction Watch reports that PNAS has issued expressions of concern about two papers from Ohio State's Carlo Croce.

Bit of a Specter

Ohio State University's Carlo Croce is facing new allegations of research misconduct, according to the New York Times.

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

HudsonAlpha researchers are expected to sequence 20,000 patient tumor and non-tumor samples for ORIEN's Avatar initiative by 2019.

Pages

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.